Sarepta Therapeutics (SRPT) Falls on New Short Report

Biotech darling Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is under heavy pressure Wednesday (-9.4%) in part on a new short report from Favus. The report claims that the clinical trial data for eteplirsen is not enough for early/accelerated FDA approval, and eteplirsen likely does not work at all.

On twitter, TheStreet's biotech master Adam Feuerstein (@adamfeuerstein) said the report "is just a rehash of old short arguments."

A screen-grab of the first page of the report can be seen here.

Here's a screen grab of Favus' $SRPT short report. First page --> pic.twitter.com/0ksTkIB9Ep

— Adam Feuerstein (@adamfeuerstein) October 9, 2013

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Scorpion Capital says short Twist Biosciences
• Wolfpack Research: 'we are short FTK because their $400m deal has been canceled'